NMOSD – Medxy AI

Why the New MS Diagnostic Criteria Require Caution: High Frequency of MOGAD and NMOSD in Optic Neuritis Patients

By MedXY 03/30/2026

A retrospective study reveals that 24% of patients meeting the latest MS criteria following optic neuritis actually have MOGAD or NMOSD, emphasizing the need for antibody testing to prevent misdiagnosis.

Neurology news Ophthalmology

Navigating the Diagnostic Overlap: Why 24 Percent of Patients Meeting Minimal MS Criteria for Optic Neuritis Require Antibody Testing

By MedXY 03/18/2026

A multicenter study reveals that nearly one-quarter of patients meeting the newest multiple sclerosis criteria for optic neuritis actually have MOGAD or NMOSD, emphasizing the critical role of antibody screening and detailed orbital MRI in clinical practice.

Clinical Updates Neurology news

Age at Onset and Clinical Trajectory in AQP4-IgG NMOSD: Decoupling Relapse Risk from Disability Accrual

By MedXY 03/06/2026

This review analyzes how age at onset influences NMOSD, revealing that while relapse risk remains constant across age groups, older onset significantly accelerates disability progression, necessitating early high-efficacy therapy.

Neurology news

Long-Term Success of Satralizumab in Managing NMOSD: Insights from the SAkuraMoon Study

By MedXY 10/23/2025

This article reviews the long-term safety and efficacy of satralizumab in neuromyelitis optica spectrum disorder based on the SAkuraMoon extension trial.